Prof. Stroes discusses the role of residual inflammatory risk in diabetes and CKD and how epigenetics could play a role in reducing this risk.
A subanalysis of the NAVIGATOR-trial showed a significant association between physical activity and reduced risk of the development of diabetes in patients at high CVD risk, independent of gender.
An Expert Consensus Panel recommends that clinical genetic testing becomes standard care for patients with definite or suspicion of FH, as well as for their at-risk relatives, to improve risk stratification, diagnosis and early treatment.
Obese patients with T2DM, who underwent bariatric surgery, had a two-fold risk reduction of microvascular complications compared with matched controls.
In a meta-analysis of statins and non-statins, LDL-c reductions reaching to a median of 0.5 mmol/L (21 mg/dL) in patients starting with median LDL-c levels of 1.6-1.8 mmol/L (63 mg/dL) are associated with lower risk of major vascular events.
A randomized trial using continuous heart monitoring, showed that the selective I-kur-inhibitor S66913 was safe, but had no clinically meaningful effect in patients with symptomatic paroxysmal AF.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
In patients with chronic kidney disease, sacubitril/valsartan had similar effects on renal function compared with irbesartan after 12 months of therapy. ARNI therapy did lower BP, NT-proBNP and troponin.
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.
Statin exposure was significantly associated with histologically confirmed idiopathic inflammatory myositis, suggesting that this potential risk should be taken into account when prescribing statins.
Analyses of the CANVAS data show that in T2DM patients, canagliflozin reduced the risk of CV death or HF hospitalization particularly in patients with a history of HF at baseline.
The US Preventive Services Task Force (USPSTF) found evidence that adding the non-traditional risk factors ABI, hsCRP and CAC could slightly improve current CVD risk assessment, but the clinical meaning is unknown.